DDInter927 DDInter1081
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent. Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with
Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label].
Lithium carbonate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Doxycycline
Lithium carbonate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Lithium carbonate {u} may lead to a major life threatening interaction when taken with {v} Cisapride
Lithium carbonate {u} may lead to a major life threatening interaction when taken with {v} Ivosidenib
Lithium carbonate may cause a minor interaction that can limit clinical effects when taken with Doxycycline
Lithium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Lithium carbonate may lead to a major life threatening interaction when taken with Cisapride
Lithium carbonate may lead to a major life threatening interaction when taken with Ivosidenib